港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

醫藥外包概念

1,606.246

-86.870-5.13%

漲家數：- -

跌家數：7

平家數：1

市盈率：- -

高：1,725.495

開：1,693.116

低：1,596.227

收：1,693.116

資料載入中...

【石藥集團(01093.HK)：SYH2068注射液(雙鏈小幹擾RNA藥物)獲臨牀試驗批准】石藥集團(01093.HK)發佈公告，本集團自主研發的化學1類新藥SYH2068注射液(雙鏈小幹擾RNA (si RNA)藥物)(該產品)已獲得中華人民共和國國家藥品監督管理局批准，可以在中國開展臨牀試驗。

石藥集團(01093)：SYH2068注射液(雙鏈小幹擾RNA藥物)獲臨牀試驗批准

易方達基金增持泰格醫藥(03347)37.21萬股每股作價約26.19港元

智通财经网

康臣藥業：收到SK-09片臨牀試驗批准通知書

藥明康德(02359)4月25日斥資2000.58萬元回購34.93萬股A股

康臣藥業(01681.HK)治療腎臟疾病藥物於中國獲批開展臨牀試驗

阿斯达克财经

康臣藥業(01681)收到SK-09片的《藥物臨牀試驗批准通知書》

康龍化成04月25日遭主力拋售844萬元

金斯瑞生物科技04月25日主力淨流出1424萬元散戶資金買入

藥明康德(02359)出現大手賣出24.65萬股，成交價$57.3，涉資1.412千萬

阿斯达克财经

基石藥業（蘇州）有限公司藥品申請臨牀試驗默示許可獲受理

港股概念追蹤 | 七部門發文推進醫藥工業數智化轉型 AI製藥展現較大潛力(附概念股)

康龍化成收盤上漲1.58%，滾動市盈率22.88倍，總市值410.41億元

藥明康德(02359)4月24日斥資2000.49萬元回購35.27萬股A股

維亞生物04月24日主力淨流入40萬元散戶資金拋售

昭衍新藥04月24日遭主力拋售459萬元

金斯瑞生物科技股份有限公司與NSG Bio達成合作，推動生物技術創新發展GenScript Biotech Enters into Partnership with NSG Bio to Boost Biotech Innovation

宜明昂科-B盤中漲超10% MC-003/IMM72臨牀試驗申請獲國家藥監局受理

港股異動 | 宜明昂科-B(01541)盤中漲超10% MC-003/IMM72臨牀試驗申請獲國家藥監局受理

康龍化成盤中異動急速拉昇5.15%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1576/news?page=9"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"醫藥外包概念","latestPrice":1606.2461,"timestamp":1746605303362,"preClose":1693.1162,"halted":0,"volume":125803953,"delay":0,"changeRate":-0.051308,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":-86.870117,"latestTime":"05-07 16:00:00","open":1693.1162,"high":1725.4948,"low":1596.227,"amount":2668796398,"amplitude":0.076349,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1746667800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1746581400000,1746590400000],[1746594000000,1746604800000]],"pbRate":2.032534,"peRate":9.743367,"turnoverRate":0.010538,"increases":0,"decrements":7,"flats":1,"marketCap":348602656000,"floatMarketCap":150577516416},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1725.4948,"amplitude":0.076349,"preClose":1693.1162,"low":1596.227,"pbRate":"2.032534","latestPrice":1606.2461,"volume":125803953,"delay":0,"open":1693.1162,"prevYearClose":1395.7731,"prevWeekClose":1741.969,"prevMonthClose":1656.921,"prevQuarterClose":1941.338,"fiveDayClose":1653.998,"twentyDayClose":1902.003,"sixtyDayClose":1520.761,"secType":"PLATE","market":"HK","turnoverRate":0.010538,"peRate":9.743367,"marketCap":348602656000,"floatMarketCap":150577516416,"timestamp":1746605303362,"nameCN":"醫藥外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":0,"down":7,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:20,pageCount:9,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530818993","title":"【石藥集團(01093.HK)：SYH2068注射液(雙鏈小幹擾RNA藥物)獲臨牀試驗批准】石藥集團(01093.HK)發佈公告，本集團自主研發的化學1類新藥SYH2068注射液(雙鏈小幹擾RNA (si RNA)藥物)(該產品)已獲得中華人民共和國國家藥品監督管理局批准，可以在中國開展臨牀試驗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2530818993","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530818993?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 19:27","pubTimestamp":1745580475,"startTime":"0","endTime":"0","summary":"石药集团(01093.HK)发布公告，本集团自主研发的化学1类新药SYH2068注射液(双链小干扰RNA (si RNA)药物)(该产品)已获得中华人民共和国国家药品监督管理局批准，可以在中国开展临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/25192749891416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SG9999004220.SGD","BK1141","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","LU1152091168.USD","BK4505","LU0326950275.SGD","LU0501845795.SGD","LU1951186391.HKD","IE00B031HY20.USD","IE0008369823.USD","BK1191","IE00BZ08YS42.EUR","LU1960683339.HKD","BK1576","LU0067412154.USD","BK4588","LU1807302812.USD","LU1008478684.HKD","03347","BK4585","BK1521","01093","LU1226288253.USD","LU1226287792.SGD","LU1226287875.USD","LU0140636845.USD","IE00BZ08YR35.GBP","LU1993786604.SGD","RNA","BK1583","LU1152091754.HKD","BK1515","BK4139","LU0072913022.USD","LU1226288170.HKD","LU0880133367.SGD","IE00B543WZ88.USD","IE0008368742.USD","LU1226287529.USD"],"gpt_icon":0},{"id":"2530189536","title":"石藥集團(01093)：SYH2068注射液(雙鏈小幹擾RNA藥物)獲臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2530189536","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530189536?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 19:22","pubTimestamp":1745580178,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，本集团自主研发的化学1类新药SYH2068注射液(该产品)已获得中华人民共和国国家药品监督管理局批准，可以在中国开展临床试验。临床前研究显示，该产品在药物活性和药效持续性方面优于同类型si RNA产品，展现出药物作用效果持久、安全性好、患者依从性高等差异化优势，具有较高的临床开发价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1285242.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","IE0008369823.USD","LU1993786604.SGD","IE00B5MMRT66.SGD","LU1226287529.USD","BK1515","BK1576","LU0140636845.USD","LU0501845795.SGD","LU0072913022.USD","IE00BZ08YS42.EUR","LU0880133367.SGD","LU1226287875.USD","BK1141","LU1951186391.HKD","IE00BZ08YR35.GBP","LU1226288253.USD","SG9999004220.SGD","LU1152091168.USD","LU0067412154.USD","BK1191","LU1008478684.HKD","LU1807302812.USD","BK1583","BK4505","01093","IE00B543WZ88.USD","LU1960683339.HKD","RNA","LU0326950275.SGD","LU1152091754.HKD","IE0008368742.USD","LU1226288170.HKD","LU1226287792.SGD","BK1521","BK4585","03347","IE00B031HY20.USD","BK4588","IE00BZ08YT58.USD"],"gpt_icon":0},{"id":"2530899551","title":"易方達基金增持泰格醫藥(03347)37.21萬股 每股作價約26.19港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530899551","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530899551?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 18:50","pubTimestamp":1745578200,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示，4月22日，易方达基金增持泰格医药(03347)37.21万股，每股作价26.185港元，总金额约为974.34万港元。增持后最新持股数目为770.37万股，持股比例为6.26%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-25/doc-ineuksvt1916276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300347","BK0077","BK1141","LU1820825898.SGD","BK1583","LU1146622755.USD","BK1576","BK0028","BK0216","BK0174","03347"],"gpt_icon":0},{"id":"2530903570","title":"康臣藥業：收到SK-09片臨牀試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2530903570","media":"格隆汇","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530903570?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 17:00","pubTimestamp":1745571654,"startTime":"0","endTime":"0","summary":"格隆汇4月25日丨康臣药业(01681.HK)发布公告，公司已收到中国国家药品监督管理局签发的有关SK-09片的《药物临床试验批准通知书》。SK-09片为一类化学新药。根据披露，足细胞损伤相关肾脏疾病是一类以肾小球足细胞损伤为主要病理改变的肾脏疾病，包括糖尿病肾病、局灶节段性肾小球硬化、微小病变肾病等。患者常因得不到及时有效的治疗，最终进展为终末期肾病(ESRD)，对患者本人、家庭及社会医疗造成沉重负担。目前临床上缺乏针对足细胞保护的靶向疗法，SK-09片的临床研发有望为肾脏病患者提供更为精准有效的治疗新选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042517005494e23a18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042517005494e23a18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1606","BK1141","03347","01681","BK1583","BK1191","BK1576"],"gpt_icon":0},{"id":"2530702829","title":"藥明康德(02359)4月25日斥資2000.58萬元回購34.93萬股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2530702829","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530702829?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 16:53","pubTimestamp":1745571218,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明康德(02359)发布公告，于2025年4月25日该公司斥资人民币2000.58万元回购34.93万股A股，回购价格为每股人民币56.83-57.79元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1284975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1583","LU2045819591.USD","BK0216","603259","LU2125910500.SGD","LU1997245177.USD","LU2495084118.USD","LU0708995583.HKD","LU0052750758.USD","399300","159982","LU0456842615.SGD","02359","LU1997244956.HKD","BK1576","LU0320764599.SGD","LU2488822045.USD","LU1046422090.SGD","LU1997245094.SGD","LU2242644610.SGD"],"gpt_icon":0},{"id":"2530908783","title":"康臣藥業(01681.HK)治療腎臟疾病藥物於中國獲批開展臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2530908783","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530908783?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 16:48","pubTimestamp":1745570880,"startTime":"0","endTime":"0","summary":"康臣药业(01681.HK) 公布，已收到国家药品监督管理局签发有关“SK-09”片的《药物临床试验批准通知书》。据介绍，相关药物用于足细胞损伤相关肾脏疾病(糖尿病肾病、局灶节段性肾小球硬化及微小病变肾病等)的治疗。(js/a)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-25 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220720140431349_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220720140431349_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1436034/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1141","01681","03347","BK1191","BK1583","BK1606","BK1576"],"gpt_icon":0},{"id":"2530777099","title":"康臣藥業(01681)收到SK-09片的《藥物臨牀試驗批准通知書》","url":"https://stock-news.laohu8.com/highlight/detail?id=2530777099","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530777099?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 16:45","pubTimestamp":1745570700,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康臣药业(01681)公布，公司已收到中国国家药品监督管理局签发的有关SK-09片的《药物临床试验批准通知书》，SK-09片用于足细胞损伤相关肾脏疾病(糖尿病肾病、局灶节段性肾小球硬化及微小病变肾病等)的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1284952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1576","01681","BK1583","BK1606","03347","BK1141"],"gpt_icon":0},{"id":"2530039079","title":"康龍化成04月25日遭主力拋售844萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530039079","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530039079?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 16:15","pubTimestamp":1745568940,"startTime":"0","endTime":"0","summary":"04月25日, 康龙化成股价跌0.29%，报收13.68元，成交金额7577万元，换手率1.87%，振幅2.92%，量比0.86。康龙化成今日主力资金净流出844万元，连续3日净流出，上一交易日主力净流出587万元。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为64.29%，平均跌幅为2.38%。该股近5个交易日上涨11.42%，主力资金累计净流出1078万元；近20日主力资金累计净流出7902万元，其中净流出天数为10日。该股主力净额占比0.21%，港股市场排名2633/2647。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425170131a46690e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425170131a46690e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1576","03759"],"gpt_icon":0},{"id":"2530903614","title":"金斯瑞生物科技04月25日主力淨流出1424萬元 散戶資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2530903614","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530903614?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 16:15","pubTimestamp":1745568906,"startTime":"0","endTime":"0","summary":"04月25日, 金斯瑞生物科技股价跌1.25%，报收11.06元，成交金额1.16亿元，换手率0.48%，振幅3.21%，量比0.72。金斯瑞生物科技今日主力资金净流出1424万元，上一交易日主力净流入165万元。该股近5个交易日上涨6.12%，主力资金累计净流出2823万元；近20日主力资金累计净流出92万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425165901a4669016&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425165901a4669016&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","HK0000306685.HKD","HK0000306701.USD","BK1141","HK0000320223.HKD","HK0000320264.USD","BK1583","01548"],"gpt_icon":0},{"id":"2530974096","title":"藥明康德(02359)出現大手賣出24.65萬股，成交價$57.3，涉資1.412千萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2530974096","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530974096?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 16:08","pubTimestamp":1745568480,"startTime":"0","endTime":"0","summary":"[大手成交]药明康德(02359)在下午04:08出现大手卖出，成交量为24.65万，成交价为港币$57.3，涉资1.412千万。至目前为止，股价跌1.122%，今日最高价为$59.0，而最低价为$56.85，总成交量为1.039千万股，总成交金额港币$6.009亿。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2504258478/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU2488822045.USD","LU0052750758.USD","LU2125910500.SGD","LU2495084118.USD","LU0708995583.HKD","LU2045819591.USD","02359","LU0320764599.SGD","LU1997244956.HKD","LU2242644610.SGD","603259","LU1046422090.SGD","LU1997245177.USD","BK1141","LU1997245094.SGD","BK1583","BK0216","LU0456842615.SGD","BK1576"],"gpt_icon":0},{"id":"2530802929","title":"基石藥業（蘇州）有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530802929","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530802929?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 12:28","pubTimestamp":1745555312,"startTime":"0","endTime":"0","summary":"4月25日，据CDE官网消息，基石药业（苏州）有限公司、无锡药明合联生物技术有限公司联合申请药品“注射用CS5001”，获得临床试验默示许可，受理号CXSL2500169。基石药业（苏州）有限公司，成立于2016年，位于苏州市，是一家以从事研究和试验发展为主的企业。主要股东信息显示，基石药业（苏州）有限公司由CStone Pharm  Holding Limited持股100%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425123710974480c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425123710974480c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","02616","BK1574","BK1141","BK1576","03347"],"gpt_icon":0},{"id":"2530918358","title":"港股概念追蹤 | 七部門發文推進醫藥工業數智化轉型 AI製藥展現較大潛力(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2530918358","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530918358?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 07:17","pubTimestamp":1745536620,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月24日，国家卫健委等七部门联合印发《医药工业数智化转型实施方案》。《方案》提出，到2030年，规上医药工业企业基本实现数智化转型全覆盖，数智技术融合创新能力大幅提升，医药工业全链条数据体系进一步完善，医药工业数智化转型生态体系进一步健全。AI有望重塑传统制药范式，为新药研发带来更多可能性。目前，多数头部AI制药企业可以将药物发现效率提升50%以上，有足够的动力将现有药物发现流程逐步AI化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1284578.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","LU2242644610.SGD","02158","03759","LU0052750758.USD","BK1141","BK1189","HSTECH","02359","LU0320764599.SGD","YANG","LU2045819591.USD","LU2125910500.SGD","BK4614","BK1518","LU0708995583.HKD","01477","BK1583","BK1191","LU1046422090.SGD","BK1574","BK1617"],"gpt_icon":1},{"id":"2529670338","title":"康龍化成收盤上漲1.58%，滾動市盈率22.88倍，總市值410.41億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529670338","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529670338?lang=zh_tw&edition=fundamental","pubTime":"2025-04-24 17:44","pubTimestamp":1745487847,"startTime":"0","endTime":"0","summary":"4月24日，康龙化成今日收盘23.08元，上涨1.58%，滚动市盈率PE达到22.88倍，创15天以来新低，总市值410.41亿元。从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均45.83倍，行业中值53.44倍，康龙化成排名第16位。截至2024年年报，共有71家机构持仓康龙化成，其中基金71家，合计持股数21607.39万股，持股市值58.17亿元。最新一期业绩显示，2024年年报，公司实现营业收入122.76亿元，同比6.39%；净利润17.93亿元，同比12.01%，销售毛利率34.24%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/24174449831917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0216","BK1576","BK1141","300759","03759"],"gpt_icon":0},{"id":"2529678042","title":"藥明康德(02359)4月24日斥資2000.49萬元回購35.27萬股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2529678042","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529678042?lang=zh_tw&edition=fundamental","pubTime":"2025-04-24 16:47","pubTimestamp":1745484445,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明康德(02359)发布公告，于2025年4月24日该公司斥资人民币2000.49万元回购35.27万股A股，回购价格为每股人民币56.13-57.67元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1283967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159982","603259","BK1576","LU1997245177.USD","399300","LU2495084118.USD","BK1583","LU0320764599.SGD","BK0216","BK1141","LU0052750758.USD","LU1997245094.SGD","LU2125910500.SGD","LU0456842615.SGD","LU0708995583.HKD","LU2045819591.USD","LU2242644610.SGD","LU2488822045.USD","02359","LU1997244956.HKD","LU1046422090.SGD"],"gpt_icon":0},{"id":"2529676067","title":"維亞生物04月24日主力淨流入40萬元 散戶資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2529676067","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529676067?lang=zh_tw&edition=fundamental","pubTime":"2025-04-24 16:16","pubTimestamp":1745482561,"startTime":"0","endTime":"0","summary":"04月24日, 维亚生物股价涨0.67%，报收1.51元，成交金额541万元，换手率0.17%，振幅6.00%，量比1.73。维亚生物今日主力资金净流入40万元，上一交易日主力净流出0万元。该股近5个交易日上涨5.59%，主力资金累计净流入9万元；近20日主力资金累计净流出1038万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424165944a46517ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424165944a46517ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01873","BK1141","BK1576"],"gpt_icon":0},{"id":"2529325679","title":"昭衍新藥04月24日遭主力拋售459萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529325679","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529325679?lang=zh_tw&edition=fundamental","pubTime":"2025-04-24 16:15","pubTimestamp":1745482537,"startTime":"0","endTime":"0","summary":"04月24日, 昭衍新药股价跌2.54%，报收9.96元，成交金额8188万元，换手率6.73%，振幅6.85%，量比2.20。昭衍新药今日主力资金净流出459万元，上一交易日主力净流出187万元。该股近5个交易日下跌2.35%，主力资金累计净流出349万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出1621万元，其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424165802a46516b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424165802a46516b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","06127","BK1141"],"gpt_icon":0},{"id":"2529472706","title":"金斯瑞生物科技股份有限公司與NSG Bio達成合作，推動生物技術創新發展GenScript Biotech Enters into Partnership with NSG Bio to Boost Biotech Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2529472706","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529472706?lang=zh_tw&edition=fundamental","pubTime":"2025-04-24 14:14","pubTimestamp":1745475240,"startTime":"0","endTime":"0","summary":"GenScript Biotech has entered a strategic partnership with NSG Bio, a leading biotech incubator based in Singapore.金斯瑞生物科技股份有限公司与总部位于新加坡的领先生物技术孵化器 NSG Bio 达成了战略合作关系。Under this agreement, GenScript will offer exclusive discounted rates and technical support from its team of scientists to companies operating within NSG Bio. These services will make it easier for startups and biotech firms to access advanced technologies, helping them move more quickly from research to market..根据该协议，金斯瑞将为NSG Bio内的运营公司提供专属的折扣价格及其科学家团队的技术支持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042414142494e09154&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042414142494e09154&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000306701.USD","BK1141","BK1576","01548","HK0000320223.HKD","HK0000320264.USD","HK0000306685.HKD","BK1583"],"gpt_icon":0},{"id":"2529564614","title":"宜明昂科-B盤中漲超10% MC-003/IMM72臨牀試驗申請獲國家藥監局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2529564614","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529564614?lang=zh_tw&edition=fundamental","pubTime":"2025-04-24 11:02","pubTimestamp":1745463720,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　宜明昂科-B（01541）盘中涨超10%，截至发稿，股价上涨4.06%，现报6.66港元，成交额2048.60万港元。\n　　宜明昂科本月初公布，集团IMC-003/IMM72治疗肺动脉高压（PAH）的临床试验申请已获中国国家药监局受理。IMC-003/IMM72为通过基因改造的新一代启动素受体IIA-Fc型融合蛋白，具有更高的活性及品质。国元国际此前指出，公司前阶段因为退出港股通，股价回调，目前价值严重低估，建议积极关注。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-24/doc-ineufssw2350108.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","BK4127","BK1161","BK1141","03347","01541","BK1576","MC","LU1878469433.USD"],"gpt_icon":0},{"id":"2529619569","title":"港股異動 | 宜明昂科-B(01541)盤中漲超10% MC-003/IMM72臨牀試驗申請獲國家藥監局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2529619569","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529619569?lang=zh_tw&edition=fundamental","pubTime":"2025-04-24 10:40","pubTimestamp":1745462438,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B盘中涨超10%，截至发稿，涨5.47%，报6.75港元，成交额1751.88万港元。消息面上，宜明昂科本月初公布，集团IMC-003/IMM72治疗肺动脉高压的临床试验申请已获中国国家药监局受理。IMC-003/IMM72为通过基因改造的新一代启动素受体IIA-Fc型融合蛋白，具有更高的活性及品质。国元国际此前指出，公司前阶段因为退出港股通，股价回调，目前价值严重低估，建议积极关注。建议关注国内布局相关资产的公司，如宜明昂科等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1283780.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","LU1878469433.USD","MC","BK1583","03347","BK1141","BK4127","01541","BK1161"],"gpt_icon":0},{"id":"2529613088","title":"康龍化成盤中異動 急速拉昇5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529613088","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529613088?lang=zh_tw&edition=fundamental","pubTime":"2025-04-24 09:42","pubTimestamp":1745458948,"startTime":"0","endTime":"0","summary":"2025年04月24日早盘09时42分，康龙化成股票出现波动，股价快速上涨5.15%。截至发稿，该股报13.880港元/股，成交量193.43万股，换手率0.66%，振幅5.15%。资金方面，该股资金流入1524.34万港元，流出565.197万港元。康龙化成股票所在的药品行业中，整体涨幅为0.27%。其相关个股中，凯莱英、信达生物、康龙化成涨幅较大，振幅较大的相关个股有凯莱英、信达生物、康龙化成，振幅分别为10.44%、5.64%、5.15%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042409422894e0494e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042409422894e0494e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03759","BK1141","BK1576"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":195,"code":"91000000","status":"200"}]}}